CEO Of Australia’s Angenix Biotech Charged With Fraud
This article was originally published in PharmAsia News
Executive Summary
The CEO of Australian biotech Angenix has been charged in a Queensland court with defrauding his company of nearly $3.4 million. CEO Neil Leggett declined comment, saying he had not yet retained an attorney. The charge carries a maximum penalty of 12 years in jail. One of Angenix's prime products is ThromboView for detecting blood clots such as those that develop during long plane flights. Angenix also had been looking to enter the Chinese market with its drugs. (Click here for more